First Berlin keeps MaaT Pharma rating, price target under review

PUBT · 2d ago
First Berlin keeps MaaT Pharma rating, price target under review
  • First Berlin Equity Research kept its rating on MaaT Pharma at Under Review, with the price target also Under Review.
  • The update followed a CHMP negative opinion on MaaT013’s conditional European filing, citing limits of the single-arm ARES Phase 3 dataset.
  • Strategy now centers on PHOENIX, a global randomized Phase 3 trial versus best available therapy in about 138 patients.
  • FDA Type C feedback supports PHOENIX as a registrational trial, with first patient enrollment possible in H1 2027.
  • Cash totaled EUR 17.1 million at end-June; runway now seen through December 2026, leaving a major funding gap for PHOENIX.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maat Pharma SA published the original content used to generate this news brief via EQS News (Ref. ID: rc_27032) on October 07, 2026, and is solely responsible for the information contained therein.